In times of limited organs for transplantation, anti-HBc-positive organs can be accepted for lung transplantation to increase the number of donors. Transplant recipients should be vaccinated against hepatitis B to prevent HBV infection. However, response after HBV vaccination has only been poorly evaluated in patients with end-stage pulmonary disease.
Background
In times of limited donor resources for any solid organ transplantation, including lung transplantation for end-stage pulmonary disease, there is a mismatch between the number of transplant candidates and the number of available organs. One option to narrow this gap is to accept organs from anti-HBcpositive donors to increase the number of available organs. Anti-HBc-positive individuals account for up to 15-20% of all potential donors; therefore, inclusion of this population results in a substantial increase of potential donor organs [1, 2] . Survival of recipients of anti-HBc-positive lung transplants is not impaired compared to recipients of anti-HBc-negative organs [3] ; however, there is a risk of acquiring chronic hepatitis B virus (HBV) infection after transplantation [4] .
An effective strategy to prevent HBV transmission is vaccination of the anti-HBc-negative transplant recipient. Hepatitis B vaccination with recombinant HBsAg should be performed when candidates are on the waiting list prior to transplantation because its efficacy will be limited thereafter due to necessary immunosuppression [5, 6] . The standard vaccination course includes 3 intramuscular vaccinations at the time points zero, month 1, and month 6 [7] .
Unfortunately, systematic data from hepatitis B vaccination programs in patients wait-listed for lung transplantation are scarce. In a Spanish survey all transplant centers reported to perform hepatitis B vaccination, however, detailed data whether all three necessary vaccinations were completely administered or resulted in anti-HBs titers > 100 U/L were not published [2] . Monocentric data on 96 lung transplantation candidates described overall anti-HBs response rates of 54% after standard or accelerated vaccination schedules [5] . Alternatively, response rates may increase more after high-dose compared to standard-dose vaccination regimens [8] . Additionally, retrospective data on US heart transplant recipients indicate that only 13/29 patients achieved a sufficient anti-HBs titer after a standard intramuscular vaccination schedule with 10 µg of recombinant HBsAg [9] .
With respect to these limited data, the aim of the current study was to systematically characterize the hepatitis B vaccination program and the resulting anti-HBs titers in patients wait-listed for lung transplantation at our transplant center.
Material and Methods
All individuals with end-stage pulmonary disease listed for lung transplantation at our hospital between May 2014 and February 2015 were consecutively evaluated. Vaccination status of anti-HBc-negative patients was retrospectively determined by vaccination cards. In Germany, these vaccination cards are paper booklets distributed during childhood to document any vaccination administered during the lifetime. Anti-HBc and anti-HBs titers were analyzed with the Architect® system (Abbott, Wiesbaden, Germany). Responders, partial responders, or non-responders after HBV vaccination were defined by anti-HBs titers >100 IU/L, 10-100 IU/L, and <10 IU/L, respectively [7] .
Concomitant medications were extracted from medical charts. Patients with ongoing prednisolone therapy (2.5-20 mg per day) or repetitive prednisolone bolus therapy (40-100 mg) were classified as "long-term prednisolone" treatment. Immunosuppressants other than prednisolone were not used.
Data analysis was performed using Excel (Microsoft, Redmond, WA, USA). Statistical differences were analyzed by Fisher´s exact test (GraphPad Software, La Jolla, CA, USA). A p-value <0.05 was considered as statistically significant.
The project was evaluated and approved by the Ethics Committee of the University of Leipzig (ethics vote number 170-14-02062014). All patients provided written informed consent prior to any study-related procedures.
Results

Baseline characteristics of the study population
During the study period, 61 patients with end-stage pulmonary disease were evaluated or wait-listed for lung transplantation; 21 were excluded due to classification as non-transplant candidates (n=9), positive anti-HBc titers (n=2), death (n=2), transplantation (n=4), or incomplete data (n=4). Thus, the study population consisted of 40 anti-HBc-negative patients (50% female, age 57.2±9.9 years, COPD n=24/40, long-term prednisolone therapy n=9/40, history of smoking n=30/40). Further baseline characteristics are summarized in Table 1 . Only 1 of the patients had clinically relevant liver disease, and this patient presented with compensated Child A cirrhosis due to alpha-1 antitrypsin deficiency.
Patients considered for further analysis did not significantly differ from excluded cases concerning, age, sex, etiology of end-stage pulmonary disease, long-term steroid therapy, or concomitant diseases.
Hepatitis B vaccination schedules
Hepatitis B vaccination was performed in 34/40 (85%) patients prior to wait-listing for lung transplantation. (Table 2) . Four patients received more than 3 vaccinations (maximum 7 vaccinations during a time span of 15 years).
One patient received the baseline and first booster vaccination within 1 week as part of an accelerated vaccine schedule due to expected timely transplantation. Vaccinations with higher than the standard vaccine dose were not performed. Anti-HBs response was analyzed 36.5 (minimum 1, maximum 805) weeks after the last hepatitis B vaccination. 
Efficacy of hepatitis B vaccination
Anti-HBs titers of >100 IU/L, 10-100 IU/L, and <10 IU/L were observed in 10/34 (29.4%), 11/34 (32.4%), and 13/34 (38.2%) patients (Figure 1 ). Response to vaccination did not correlate with sex, pulmonary disease (COPD vs. non-COPD), long-term prednisolone therapy, smoking status, or co-morbidities. The age of responders, partial responders, or non-responders at the baseline vaccination did not differ significantly. The median time interval between the last hepatitis B vaccination and the titer control was 20 weeks in non-responders and 91 weeks in responders.
Discussion
Hepatitis B vaccination is recommended in solid organ transplant candidates prior to surgery [10, 11] , but existing data on hepatitis B vaccination programs in patients wait-listed for lung or heart transplantation are limited by small patient numbers, retrospective analysis, or single-center study design [5, 8, 9] .
In our cohort, hepatitis B vaccination was administered to 85% of patients. Spanish data report that all national transplant centers regularly vaccinate against hepatitis B in patients on the waiting list for lung transplantation, although none quantify the level of anti-HBs titers [12] . However, quantification of anti-HBs titers is important, because 38.2% of our vaccinated study population did not reach anti-HBs titers >10 IU/L while on the waiting list. Galar et al. reported overall anti-HBs response rates of 54.2% [5] . Unfortunately, they did not provide detailed anti-HBs titers, so their results are difficult to compare with our study.
Anti-HBs titers should be quantified 4-8 weeks after the third hepatitis B vaccination of a standard vaccination course [7] . Unfortunately, due to our retrospective study design we did not have any data at this time point, but analyzed the time interval between the initial and the last administered hepatitis B vaccination and the time point of the current study evaluation.
Reasons for impaired anti-HBs immunity after vaccination are numerous and include advanced age at initiation of the vaccination schedule, history of smoking, immunosuppression, male sex, and advanced end-stage pulmonary or heart disease [5, 9] . Similar correlations were not observed in our study. These results should not be overinterpreted due to the limited number of patients and the single-center study design. difference was not statistically significant, but is again impaired by the small cohort size. Alternative treatment options include additional booster vaccinations [9] , accelerated vaccination schedules [5] , or high-dose booster vaccinations [8] . However, these alternatives have not been evaluated in large prospective controlled trials and reach sufficient anti-HBs titers in only about 50% of cases. In our cohort, 4 patients received more than 3 hepatitis B vaccinations, and all developed an anti-HBs titer >10 IU/L. If booster vaccinations do not induce sufficient humoral immunity, prophylactic treatment with an HBV nucleos(t)ide analogue (e.g., lamivudine) may be another option to prevent hepatitis B infection after transplantation of an anti-HBc-positive organ [14] .
Conclusions
Although 85% of patients on the waiting list for lung transplantation were vaccinated against hepatitis B, 38.2% did not present with an anti-HBs Titer >10 IU/L. Thus, titer controls after hepatitis B vaccination should be regularly monitored.
In case of insufficient immunity, patients should be considered for additional booster vaccinations, alternative vaccination schedules, or prophylactic treatment with a nucleos(t)ide analogue to prevent hepatitis B infection in case of transplantation of an anti-HBc-positive donor organ.
